Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 9/20 | 0.40 |
| ▸ | POLB | P06746 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4052261 | 0.82 | TDP1 (0.45) | MEN1KMT2AGAAMAPTTDP1 | |
| SCHEMBL4055523 | 0.80 | BCHE (0.56) | MAPTALDH1A1 | |
| SCHEMBL4049521 | 0.77 | TDP1 (0.48) | MEN1KMT2AGAAMAPTTDP1 | |
| SCHEMBL4049010 | 0.76 | MEN1 (0.46) | MEN1KMT2AGAAMAPTTDP1 | |
| SCHEMBL29071485 | 0.72 | MAPT (0.60) | MEN1KMT2AGAAMAPTTDP1 | |
| SCHEMBL5279510 | 0.71 | HDAC3 (0.56) | MAPTALDH1A1 | |
| SCHEMBL4047830 | 0.71 | MAPT (0.47) | MEN1KMT2AMAPTTDP1ATM | |
| SCHEMBL4052446 | 0.71 | MAPT (0.47) | MEN1KMT2AGAAMAPTTDP1 | |
| SCHEMBL29071222 | 0.70 | MAPT (0.58) | MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL24580520 | 0.70 | MEN1 (0.63) | MEN1KMT2AGAAMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009026701-A1 | SIRTUIN INHIBITORS | METHYLGENE INC. (CA) | 2009-03-05 | — | — | WO | disclosed |